Plantar Wart Removers

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of plantar warts. It provides relief from pain associated with plantar warts through its wart removal action.

There are no teratogenic or nonteratogenic effects mentioned in the available data.

Dosage and Administration

The affected area should be washed and dried thoroughly prior to application. If necessary, the medicated disc may be cut to fit the size of the plantar wart. The medicated disc should be applied with the sticky side adhering to the skin, and it must be covered with the enclosed cushion.

After 48 hours, the medicated disc should be removed. This procedure may be repeated every 48 hours as needed for a maximum duration of 14 days, or until the plantar wart is completely removed. To assist in the removal process, soaking the plantar wart in warm water for 5 minutes prior to application is recommended.

Contraindications

Use is contraindicated in the following situations:

Patients with diabetes should not use this product due to potential complications associated with glycemic control.

Individuals with poor blood circulation are advised against use, as this may exacerbate their condition and lead to further complications.

Application is contraindicated on irritated skin or any area that is infected or reddened, as this may worsen the irritation or infection.

Warnings and Precautions

For external use only. This product should be kept out of reach of children to prevent accidental ingestion. In the event of swallowing, immediate medical assistance should be sought, or contact a Poison Control Center without delay.

This product is contraindicated for individuals with diabetes or those who have poor blood circulation. It is also advised not to apply the product on irritated skin or any area that is infected or reddened, as this may exacerbate the condition.

Healthcare professionals should instruct patients to discontinue use and consult a physician if discomfort persists. Regular monitoring of the skin condition is recommended to ensure safety and efficacy during use.

Side Effects

For external use only. Patients are advised to stop use and consult a doctor if discomfort lasts.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Plantar Wart Removers (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Safety during pregnancy has not been established for this medication. It is contraindicated for use during pregnancy due to potential risks to the fetus. Healthcare professionals should advise pregnant patients to avoid this medication and consider alternative treatments that have a more established safety profile during pregnancy. Women of childbearing potential should be informed of these risks and the importance of effective contraception while using this medication.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or its effects during lactation. Healthcare professionals should consider the lack of data when advising lactating mothers about the use of this medication. The potential risks and benefits should be carefully evaluated in the context of the individual patient's situation.

Renal Impairment

Patients with renal impairment may not have specific dosage adjustments, special monitoring, or safety considerations outlined in the prescribing information. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment and individualized patient assessment. Regular monitoring of renal function is advisable to ensure patient safety and therapeutic efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

There is currently no specific information available regarding overdosage for this medication. In the absence of documented overdosage data, healthcare professionals are advised to exercise caution and monitor patients closely for any unusual symptoms or adverse effects that may arise following administration.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Monitoring of vital signs and laboratory parameters may be warranted to assess the patient's condition and guide further management.

Healthcare professionals should remain vigilant for potential symptoms that could indicate an overdosage scenario, although specific symptoms have not been detailed. If any adverse reactions or unexpected clinical presentations occur, appropriate medical intervention should be sought immediately.

For further guidance, healthcare providers are encouraged to consult local poison control centers or relevant medical authorities to obtain the most current recommendations for managing suspected overdosage cases.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the provided text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. In the event that the medication is swallowed, patients should be instructed to seek medical help or contact a Poison Control Center immediately.

Additionally, patients should be informed to discontinue use and consult a doctor if they experience any discomfort that persists. This guidance is essential to ensure patient safety and appropriate management of any adverse effects.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at a controlled temperature range of 20° to 25°C (68° to 77°F). Care should be taken to protect the product from excessive heat and to avoid exposure to temperatures exceeding 40°C (140°F). Proper storage conditions are crucial to maintain the integrity and efficacy of the product.

Additional Clinical Information

The medicated disc is intended for topical administration, with the application method involving adherence of the sticky side to the skin. The disc should be removed after 48 hours, and the procedure can be repeated every 48 hours as necessary for up to 14 days, or until the plantar wart is removed.

Clinicians should counsel patients that the product is for external use only. Special caution is advised for individuals who are diabetic or have poor blood circulation, as well as for use on irritated, infected, or reddened skin. Patients should discontinue use and consult a doctor if discomfort persists. It is important to keep the product out of reach of children, and in the event of ingestion, medical assistance or contact with a Poison Control Center should be sought immediately.

Drug Information (PDF)

This file contains official product information for Plantar Wart Removers, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)